ElectroCore Inc (ECOR)

NASDAQHealth CareMedical - DevicesSnapshot 2026-10-23

$7.05-4.86%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge ElectroCore Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	11.96M
EPS	—	-0.206
FY 2026 · Annual
Revenue	—	41.92M
EPS	—	-1.376
Revenue growth	About 30%	—
FY 2027 · Annual
Revenue	—	53.44M
EPS	—	-0.623

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Reduce losses and improve earnings trajectory	A supporting condition in ElectroCore Inc's published investment case. The stated target is EPS loss narrows from -$1.5 in 2026 to less negative in 2027.	Improving	EPS loss worsens or remains flat beyond 2027	Diluted EPS: $-0.33 per share FY2026-Q2; GAAP. Published target: EPS loss narrows from -$1.5 in 2026 to less negative in 2027. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026-0.33 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 73e33f4f-75d4-42fc-84e9-26775e535772. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Improve gross profit margins through operational efficiencies	Gross profit improved from $7.5M in 2025-Q3 to $8.4M in 2026-Q1.	Under Pressure	gross profit margin declines below 2025-Q3 levels persistently	Gross margin: 86.53% FY2026-Q2; GAAP. Published target: gross profit margin improves or remains stable relative to 2026-Q1 levels. Target percentage unit is not explicit. Source published Aug 6, 202686.529101 percent · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 73e33f4f-75d4-42fc-84e9-26775e535772. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Achieve approximately 30% annual revenue growth in 2026	A primary condition in ElectroCore Inc's published investment case. The stated target is >=30% annual growth in 2026.	Improving	annual revenue growth falls below 15% in 2026	Revenue growth: 28.03% FY2026-Q2; GAAP. Published target: >=30% annual growth in 2026. Target period is not explicitly aligned with this observation. Source published Aug 6, 202628.031432 percent · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 73e33f4f-75d4-42fc-84e9-26775e535772. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Revenue grew from $7.4 million in 2025-Q2 to $9.5 million in 2026-Q2, a 28% increase. Management raised full-year 2026 revenue guidance to greater than 30% growth over 2025, consistent with the trajectory of quarterly revenue growth, indicating delivery on this priority. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenueUnavailable

Unavailable → Unavailable · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	3 / 4
2026-07-25	Unavailable	Unavailable	3 / 4
2026-07-26	Unavailable	$54,228,200	4 / 5
2026-07-27	Unavailable	$54,228,200	4 / 5
2026-07-28	Unavailable	$54,228,200	4 / 5
2026-07-29	Unavailable	Unavailable	3 / 4
2026-07-30	Unavailable	$54,228,200	4 / 5
2026-07-31	Unavailable	$54,228,200	4 / 5
2026-08-01	Unavailable	Unavailable	3 / 4
2026-08-02	Unavailable	$54,228,200	4 / 5
2026-08-03	Unavailable	Unavailable	3 / 4
2026-08-04	Unavailable	Unavailable	3 / 4
2026-08-05	Unavailable	Unavailable	3 / 4
2026-08-06	Unavailable	$54,228,200	4 / 5
2026-08-07	Unavailable	Unavailable	3 / 4
2026-08-08	Unavailable	$54,228,200	4 / 5
2026-08-09	Unavailable	$54,228,200	4 / 5
2026-08-10	Unavailable	$54,228,200	4 / 5
2026-08-11	Unavailable	Unavailable	3 / 4
2026-08-12	Unavailable	$54,366,800	3 / 5
2026-08-13	Unavailable	$54,366,800	3 / 5
2026-08-14	Unavailable	Unavailable	3 / 4
2026-08-15	Unavailable	Unavailable	3 / 4
2026-08-16	Unavailable	Unavailable	3 / 4
2026-08-17	Unavailable	Unavailable	3 / 4
2026-08-18	Unavailable	Unavailable	3 / 4
2026-08-19	Unavailable	Unavailable	3 / 4
2026-08-20	Unavailable	Unavailable	3 / 4
2026-08-21	Unavailable	Unavailable	3 / 4
2026-08-22	Unavailable	Unavailable	3 / 4
2026-08-23	Unavailable	Unavailable	3 / 4
2026-08-24	Unavailable	Unavailable	3 / 4
2026-08-25	Unavailable	Unavailable	3 / 4
2026-08-26	Unavailable	Unavailable	3 / 4
2026-08-27	Unavailable	Unavailable	3 / 4
2026-08-28	Unavailable	Unavailable	3 / 4
2026-08-29	Unavailable	Unavailable	3 / 4
2026-08-30	Unavailable	Unavailable	3 / 4
2026-08-31	Unavailable	Unavailable	3 / 4
2026-09-01	Unavailable	Unavailable	3 / 4
2026-09-02	Unavailable	Unavailable	3 / 4
2026-09-03	Unavailable	Unavailable	3 / 4
2026-09-04	Unavailable	Unavailable	3 / 4
2026-09-05	Unavailable	Unavailable	3 / 4
2026-09-06	Unavailable	Unavailable	3 / 4
2026-09-07	Unavailable	Unavailable	3 / 4
2026-09-08	Unavailable	Unavailable	3 / 4
2026-09-09	Unavailable	Unavailable	3 / 4
2026-09-10	Unavailable	Unavailable	3 / 4
2026-09-11	Unavailable	Unavailable	3 / 4
2026-09-12	Unavailable	Unavailable	3 / 4
2026-09-13	Unavailable	Unavailable	3 / 4
2026-09-14	Unavailable	Unavailable	3 / 4
2026-09-15	Unavailable	Unavailable	3 / 4
2026-09-16	Unavailable	Unavailable	3 / 4
2026-09-17	Unavailable	Unavailable	3 / 4
2026-09-18	Unavailable	Unavailable	3 / 4
2026-09-19	Unavailable	Unavailable	3 / 4
2026-09-20	Unavailable	Unavailable	3 / 4
2026-09-21	Unavailable	Unavailable	3 / 4
2026-09-22	Unavailable	Unavailable	3 / 4
2026-09-23	Unavailable	Unavailable	3 / 4
2026-09-24	Unavailable	Unavailable	3 / 4
2026-09-25	Unavailable	Unavailable	3 / 4
2026-09-26	Unavailable	Unavailable	3 / 4
2026-09-27	Unavailable	Unavailable	3 / 4
2026-09-28	Unavailable	Unavailable	3 / 4
2026-09-29	Unavailable	Unavailable	3 / 4
2026-09-30	Unavailable	Unavailable	3 / 4
2026-10-01	Unavailable	Unavailable	3 / 4
2026-10-02	Unavailable	Unavailable	3 / 4
2026-10-03	Unavailable	Unavailable	3 / 4
2026-10-04	Unavailable	Unavailable	3 / 4
2026-10-05	Unavailable	Unavailable	3 / 4
2026-10-06	Unavailable	Unavailable	3 / 4
2026-10-07	Unavailable	Unavailable	3 / 4
2026-10-08	Unavailable	Unavailable	3 / 4
2026-10-09	Unavailable	Unavailable	3 / 4
2026-10-10	Unavailable	Unavailable	3 / 4
2026-10-11	Unavailable	Unavailable	3 / 4
2026-10-12	Unavailable	Unavailable	3 / 4
2026-10-13	Unavailable	Unavailable	3 / 4
2026-10-14	Unavailable	Unavailable	3 / 4
2026-10-15	Unavailable	Unavailable	3 / 4
2026-10-16	Unavailable	Unavailable	3 / 4
2026-10-17	Unavailable	Unavailable	3 / 4
2026-10-18	Unavailable	Unavailable	3 / 4
2026-10-19	Unavailable	Unavailable	3 / 4
2026-10-20	Unavailable	Unavailable	3 / 4
2026-10-21	Unavailable	Unavailable	3 / 4
2026-10-22	Unavailable	Unavailable	3 / 4
2026-10-23	Unavailable	Unavailable	3 / 4
2026-10-24	Unavailable	Unavailable	3 / 4

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	5	0	0
2026-06-01	5	0	0
2026-07-01	5	0	0
2026-08-01	5	0	0
2026-09-01	5	0	0
2026-10-01	5	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 5 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Reduce losses and improve earnings trajectoryDiluted EPS: $-0.33 per share
Improve gross profit margins through operational efficienciesPublished status: Under Pressure
Achieve approximately 30% annual revenue growth in 2026Revenue growth: 28.03%

Next proof point

Nov 4, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.8%Typical daily move · historical

Downside history

-44.1%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

ElectroCore Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative growth business, not yet a profitable compounder. The long-term thesis is on watch: revenue growth and VA-channel expansion are progressing, but recent financial performance trails its industry cohort and losses remain.

What's priced into ElectroCore Inc

The evidence snapshot gives no valuation multiple or direct measure of market expectations, so valuation cannot be described reliably. The clearest expectation is management’s raised 2026 revenue guidance for growth above 30%, alongside a goal of positive adjusted EBITDA by Q3 2027.

What the fundamentals likely do

Near term, revenue growth and VA prescriptions support the business, and adjusted EBITDA losses have narrowed, but the company is still loss-making. The main execution test is whether growth continues and losses keep shrinking; a guidance reversal would also damage management credibility.

What ElectroCore Inc hinges on

The multi-year view hinges on delivering the raised revenue outlook and reaching positive adjusted EBITDA on the stated timeline. Weakening jobs data could pressure cyclical healthcare names, while continued strong results from sector bellwethers could support the sector backdrop.